Key Highlights

● Maravai LifeSciences fell on Tuesday, September 29, 2026, and the move was attributed to profit-taking after a rapid run-up.

● The reports cited no specific reason, and the decline matched a soft day for small caps and health care stocks.

● Maravai's nucleic acid business, including TriLink BioTechnologies, makes materials used in mRNA therapies and vaccines.

● The 10-year Treasury Yield reached its highest since at least 2007, which hits smaller growth-oriented companies hardest.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) fell on Tuesday, September 29, 2026, as traders locked in profits after a rapid run-up in the stock. Maravai was listed among the day's decliners, and the move was attributed to profit-taking after a rapid run-up. No specific reason was reported.

Profit-Taking, Not News

Profit-taking is what it sounds like: investors who bought before a strong rally sell some shares to lock in gains. After a stock rises quickly in a short period, some pullback is common, even when nothing about the company has changed. The explanation pointed to recent momentum rather than any announcement, and the move was in line with a soft day for small caps and health care.

What Maravai Does

Maravai, based in San Diego, supplies critical ingredients and tools used to develop and manufacture drugs, vaccines and diagnostics. Its nucleic acid production business, which includes TriLink BioTechnologies, makes materials used in messenger RNA, or mRNA, therapies and vaccines, including its CleanCap capping technology. It also has a Biologics safety testing Business that helps drugmakers detect impurities during production.

A Pandemic Boom and a Cooling

The company's fortunes surged during the pandemic, when Demand for mRNA Vaccine materials soared, and then cooled as that demand faded. Since then, investors have watched for signs of recovery in customers' research and Manufacturing activity.

A Tough Day for Health Care and Small Caps

Health care was among the declining sectors at midday, and uniQure plunged after four-year data for its Huntington's disease gene therapy. The Russell 2000 finished lower, with closing figures from different sources clustered between roughly 2,807 and 2,810.

Rates Were the Main Story

Rising long-term Treasury yields pressured stocks throughout the day. The 30-year yield hit its highest level since 2002, and the 10-year reached its highest since at least 2007. Higher yields tend to hit smaller, growth-oriented companies hardest, since their value depends more on Earnings further in the future.

What Investors Track

Investors will look for the next quarterly update for evidence of demand trends in the nucleic acid and biologics safety testing businesses. GDP and August PCE Inflation arrive on Wednesday, September 30, Nike reports on Thursday, October 1, and the September jobs report follows on Friday, October 2. New York Fed President John Williams said there is no need for urgency after the central bank's September meeting, and odds of an October rate hike fell to roughly a coin flip.